Ann: Canine Cancer Trial Update, page-214

Suppose you could could contact Dr Aston or Calvary Health Care, Bethlehem, Melbourne or the Centre for Motor Neurone Disease Research Faculty Medicine and Health Research at Macquarie University.
I am sure they could point you in the Direction of Dr Susan Mathers or Professor Dominic Rowe who are doing the trial.

First Patient Dosed in Motor Neurone Disease Phase 1/2 Trial
● Clinical Study Protocol minor amendments to speed recruitment
● Additional patients currently undergoing screening
3 October 2022 – Perth, Australia: PharmAust Limited (ASXAA & PAAO), a clinical-stage
biotechnology company, is pleased to report the first patient has been dosed in its Phase 1/2
Trial testing the effects of monepantel (MPL) in individuals living with motor neurone disease
(MND).
Also ethics approval has been granted to make a few small amendments to the Clinical Study
Protocol to refine the study design and accelerate recruitment.
The trial is testing the safety and tolerability of MPL in patients living with MND. It will also look
for signs that MPL can slow the progression of MND. This data, with concurrent animal studies,
will determine whether MPL should proceed to larger Phase 2 studies.
PharmAust previously announced it received a funding commitment of A$881,085 for a Phase
1/2 trial examining the effects of MPL in MND, otherwise known as Lou Gehrig’s disease or
Amyotrophic Lateral Sclerosis (ALS). These funds were granted by FightMND, the largest
independent funder of MND research in Australia. The trial is overseen by Dr Susan Mathers
of Calvary Health Care, Bethlehem, Melbourne and will include a second trial site headed by
Professor Dominic Rowe of the Centre for Motor Neurone Disease Research Faculty of
Medicine and Health Research at Macquarie University, Sydney.
The funding agreement provides that PharmAust shall own all intellectual property generated
from the trial.
The third instalment of $173,034.80 is now payable upon recruitment of the first patient. Further
instalments for a total of $881,085 will be paid by FightMND to PharmAust as clinical trial
milestones are met.
This announcement is authorised by the Board
Enquiries:
Dr Roger Aston
Executive Chairman
[email protected]
P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com